Illumina Analysts Slash Their Forecasts Following Q4 Results

Comments
Loading...

Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.

The company posted quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 92 cents per share. The company reported quarterly sales of $1.10 billion which beat the analyst consensus estimate of $1.08 billion.

“The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, margin expansion, and EPS growth,” said Jacob Thaysen, Chief Executive Officer. “For 2025, we will continue our transformation, executing our refreshed strategy that prioritizes a sharp focus on customers and our own operational excellence in order to drive Illumina forward.”

Illumina said it sees FY2025 adjusted earnings of $4.50 to $4.65 per share, versus estimates of $4.13 per share. The company affirmed FY2025 sales guidance of $4.28 billion to $4.40 billion.

Illumina shares fell 8.2% to trade at $112.77 on Friday.

These analysts made changes to their price targets on Illumina following earnings announcement.

  • Guggenheim analyst Subbu Nambi maintained Illumina with a Buy and lowered the price target from $170 to $150.
  • Canaccord Genuity analyst Kyle Mikson maintained the stock with a Hold and lowered the price target from $145 to $135.

Considering buying ILMN stock? Here’s what analysts think:

Read This Next:

ILMN Logo
ILMNIllumina Inc
$71.26-6.61%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
13.15
Growth
7.86
Quality
-
Value
45.47
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech companies could follow Illumina's trend?
How will competitors in genomics react to Illumina's strategy?
What impact will market sentiment have on Illumina's stock?
Are there investment opportunities in related health tech?
How might analyst downgrades affect investor behavior?
Could Illumina's margin expansion attract new investors?
Which healthcare ETFs might benefit from Illumina's performance?
How will innovations in sequencing shape the market?
What other stocks could be impacted by Illumina's outlook?
Which industries could see growth from genomic advancements?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: